An Open-Label Extension Trial of the Long Term Safety of Oral BIBF 1120 in Patients with Idiopathic Pulmonary Fibrosis (IPF)

Investigator: Harold Collard, MD
Sponsor: Boehringer Ingleheim

Location(s): United States


The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow up period in the double-blind phase III placebo controlled parent trials (1199.32 and 1199.34), who wish to continue treatment with BIBF 1120.